Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$71.40
▼ $1.62 (-2.2%)
Market data updated: 09/19 10:43 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$29.50B
Day Range
$71.40 - $73.05
52-Week Range
$71.00 - $148.79
Beta
—
Next Earnings
02.11.2026
Support
$71.00
Resistance
$80.17
ZTS is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-50.3% (1Y)
Strengths: 8/29 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Return on equity (ROE)
Return on equity (ROE): 80.2% — strong
Fundamental
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: -0.41 (3y annualized return -26.3% / max drawdown 64.1%)
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
46
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
53
Quality
50
Value
55
Momentum
19
Risk
42
Sentiment
44
Fundamental
70
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
SCANNING ZTS...
Recent media coverage of Zoetis has focused on its stock performance and industry positioning. The company’s shares dropped following an earnings revision, drawing attention from investors like Impax Asset Management. Additionally, Zoetis was highlighted in a veterinary diagnostics market report projecting strong growth through 2030, comparing its standing with competitors like IDEXX and Thermo Fisher. Analysts remain cautiously optimistic despite the stock underperforming the S&P 500, while Zoetis leadership is set to participate in the Morgan Stanley Global Healthcare Conference.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Zoetis. News trend score: 44. Reason: 7 of the last 20 articles are negative, versus 6 positive.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
13
🎯 Conviction (vs. Emotion)
38
Psychology
45
Fundamentals
70
Technical
19
Valuation
55
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-7%
Market Narrative
31
Fundamental Reality
38
Narrative Gap
-7
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s dominant herding behavior reflects ZTS’s synchronized movement with peers, likely driven by sector-wide positioning rather than stock-specific catalysts. Loss aversion and anchoring (37/30 scores) suggest traders are hesitant to exit near support, while subdued volume (0.89x avg) and negative momentum (-1.9% ROC) temper panic or FOMO. The narrative gap (21 points) hints at a disconnect between optimistic sentiment (100/100) and technical weakness. The key question is whether herding persists or if loss aversion breaks under further downside, given the 3.5% proximity to support.
Updated: 09/09/2026, 12:26 PM
What could change this?
👥 What the crowd believes
"Zoetis has significantly lagged the broader market over the past year"
"The Veterinary Diagnostics industry is on a strong growth path"
"Zoetis (ZTS) emerges from decent value screen with low P/E, high profitability, and strong returns"
"Shares Drop After Earnings Revision"
📈 13D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 100/100
🔴 Weakest match
Jesse Livermore — 12/100
🗣️ Why do they disagree?
Based on the documented principles of each methodology, the model estimates that Mackay, Nelson, Veblen and Marks‑cycle assign high scores, seeing little crowd mania, a favorable cycle position, growth that matches real value creation, and an early‑mid cycle not overextended. Conversely, Graham’s defensive and enterprising criteria, Smith, Lynch, Fisher and the efficient‑market view give low to moderate scores, reflecting concerns about insufficient discount, stability or growth quality. Marks (overall) and Loeb offer mixed or moderate risk assessments, indicating a good business but potentially high expectations, while Schwager finds no clear edge. The most bearish assessments from Housel and Livermore highlight volatility and a negative trend, which under their rules make the stock unattractive.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 100
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 89
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 81
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 80
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 69
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 68
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 49
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 49
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 45
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 44
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 38
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 37
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 34
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 31
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 22
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 12
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Based on the last 279 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 8 bearish · 3 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a trading range, but the picture isn't yet clear enough on the likely direction.
Low confidence
$71.00
Range Bottom
$80.17
Range Top
50
Trading Days in Range
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
71.8%
Operating Margin
—
Net Margin
28.2%
EBITDA Margin
—
ROE
80.2%
ROA
17.3%
ROIC
—
EPS
$6.03
Cash
$2.31B
Total Debt
$9.04B
Current Ratio
3.03
Debt/Equity
2.71
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 20.7.2026 | $0.530 |
| 19.7.2026 | $0.530 |
| 20.4.2026 | $0.530 |
| 19.4.2026 | $0.530 |
| 20.1.2026 | $0.530 |
| 19.1.2026 | $0.530 |
| 31.10.2025 | $0.500 |
| 30.10.2025 | $0.500 |
| 18.7.2025 | $0.500 |
| 17.7.2025 | $0.500 |
| 21.4.2025 | $0.500 |
| 20.4.2025 | $0.500 |
How is Fair Value calculated? →
Current Price
$71.40
Estimated Fair Value (DCF)
$71.58
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+0.3%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
5.5%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 5.5% | $2.41B | $2.21B |
| 2 | 4.7% | $2.52B | $2.12B |
| 3 | 4.0% | $2.62B | $2.02B |
| 4 | 3.2% | $2.71B | $1.92B |
| 5 | 2.5% | $2.77B | $1.80B |
Base FCF (last actual year)
$2.28B
Terminal Value
$43.74B
Present Value of Terminal Value
$28.43B
Enterprise Value
$38.50B
Net Debt
$6.73B
Equity Value
$31.77B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$7.51
Tangible Book Value per Share (Tangible NAV)
-$0.98
Sentiment based on basic keywords (not AI) — 6 positive, 7 neutral, 7 negative out of the last 20 articles.
Yahoo · 18.9.2026
SeekingAlpha · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 18.9.2026
SeekingAlpha · 17.9.2026
SeekingAlpha · 17.9.2026
SeekingAlpha · 17.9.2026
SeekingAlpha · 14.9.2026
ChartMill · 14.9.2026
SeekingAlpha · 13.9.2026
Stocktwits · 11.9.2026
Yahoo · 11.9.2026
StockStory · 11.9.2026
Yahoo · 11.9.2026
Yahoo · 10.9.2026
Trefis · 10.9.2026
Yahoo · 8.9.2026
Insider Monkey · 8.9.2026
Yahoo · 7.9.2026
GlobeNewswire · 7.9.2026
Zoetis (ZTS) currently has a StockIQ AI score of 46/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ZTS currently scores 46/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, ZTS's estimated fair value is $71.58, which is 0.3% above the current price of $71.40. This is one valuation model among several signals in the fair-value category, not a price target.
ZTS's technical score is 19/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Return on equity (ROE): 80.2% — strong; Current ratio: 3.03; Gross margin: 71.8% — strong.
Based on the real signals StockIQ computed: Calmar: -0.41 (3y annualized return -26.3% / max drawdown 64.1%); Free cash flow growth: -0.7%; Debt/equity: 2.71.
Yes — ZTS has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| SACCARO JAMES | Grant/Award from Employer | 31.8.2026 | 81,063 | +81,063 | — |
| DAMELIO FRANK A | Gift | 7.8.2026 | 14,808 | -6,650 | — |
| DAMELIO FRANK A | Gift | 7.8.2026 | 6,650 | -6,650 | — |
| Joseph Wetteny | Grant/Award from Employer | 10.7.2026 | 363.053 | +363.053 | $26.22 |
| Ferran Astorga Jeannette | Grant/Award from Employer | 10.7.2026 | 45.327 | +45.327 | $26.22 |
| Lagano Roxanne | Grant/Award from Employer | 10.7.2026 | 314.645 | +314.645 | $26.22 |
| FULLER JULIE | Grant/Award from Employer | 10.7.2026 | 314.645 | +314.645 | $26.22 |
| Driscoll Rimma | Grant/Award from Employer | 10.7.2026 | 237.636 | +237.636 | $26.22 |
| Esch Kevin | Grant/Award from Employer | 10.7.2026 | 308.046 | +308.046 | $26.22 |
| Nayak Abhay U | Grant/Award from Employer | 10.7.2026 | 214.616 | +214.616 | $26.22 |
| PECK KRISTIN C | Grant/Award from Employer | 10.7.2026 | 616.089 | +616.089 | $26.22 |
| Sarbaugh Keith | Grant/Award from Employer | 10.7.2026 | 259.638 | +259.638 | $26.22 |
| Joseph Wetteny | Grant/Award from Employer | 10.7.2026 | 10,155 | +363 | $26.22 |
| PECK KRISTIN C | Grant/Award from Employer | 10.7.2026 | 66,195 | +616 | $26.22 |
| Ferran Astorga Jeannette | Grant/Award from Employer | 10.7.2026 | 2,296 | +45 | $26.22 |
| Lagano Roxanne | Grant/Award from Employer | 10.7.2026 | 30,947 | +315 | $26.22 |
| FULLER JULIE | Grant/Award from Employer | 10.7.2026 | 2,113 | +315 | $26.22 |
| Driscoll Rimma | Grant/Award from Employer | 10.7.2026 | 6,273 | +238 | $26.22 |
| Esch Kevin | Grant/Award from Employer | 10.7.2026 | 806 | +308 | $26.22 |
| Nayak Abhay U | Grant/Award from Employer | 10.7.2026 | 4,701 | +215 | $26.22 |
| Sarbaugh Keith | Grant/Award from Employer | 10.7.2026 | 2,365 | +260 | $26.22 |
| Stetter Mark | Grant/Award from Employer | 18.6.2026 | 317.622 | +317.622 | $78.71 |
| Stetter Mark | Grant/Award from Employer | 18.6.2026 | 534 | +318 | $78.71 |
| MCCALLISTER MICHAEL B | Gift | 10.6.2026 | 1,209 | -1,209 | — |
| MCCALLISTER MICHAEL B | Gift | 10.6.2026 | 0 | -1,209 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
19,430,882 shares short as of 2026-08-31 · vs. 21,352,028 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
52.1% of trading volume this week was short selling, vs. 46.1% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology